Webinar: How to Improve your Antibody Drug Development Assays with Anti-idiotypic Antibodies

Follow  Facebook twitter Linkedin You tube Pinterest
  • Do you need to develop highly sensitive PK and ADA assays?
  • Did you know that three different types of anti-drug antibody can be generated to bind specifically in different ways to your candidate monoclonal antibody drug?

These highly specialized antibodies can be used to set up pharmacokinetic (PK) assays in different formats to measure free or total drug levels in preclinical and clinical samples, or as positive controls in anti-drug antibody (ADA) assays.

Listen to our recorded webinar to find out how recombinant monoclonal anti-idiotypic antibodies are generated at Bio-Rad, and how they can be used to develop highly specific and sensitive PK and ADA assays.

The presentation covers how we use HuCAL® technology to overcome the limitations of traditional antibody generation methods, resulting in the fast development of fully human Fab and full immunoglobulin anti-idiotypic antibodies.

Data is presented to show development of antibodies binding specifically and with high affinity to well-known drugs, such as adalimumab, trastuzumab and cetuximab, plus we explain our unique capability for developing antibodies against drug-target complexes.

Webinar: Are HuCAL anti-idiotypic antibodies part of your solution?

Presented by: Dr Christian Frisch, R&D Manager, Bio-Rad Laboratories


Dr Christian Frisch, R&D Manager at Bio-Rad Laboratories Speaker Biography:

Christian Frisch is R&D manager at Bio-Rad and has led the antibody generation group since 2003. He studied molecular biology in Göttingen (Germany) and did his Ph.D. with Prof. Alan Fersht at the University of Cambridge (UK) working on the energetics of protein-protein interactions and protein folding. In 1997 he joined MorphoSys AG, working on the development of display technologies and the generation of antibody phage display libraries. His group at Bio-Rad has generated more than 25,000 antibodies for custom projects over the last 13 years.